Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation
Authors:
- 24 April 2023
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (11) , 8521-8533
Abstract
Purpose Lymphoma-associated haemophagocytic syndrome (LAHS) is a group of malignant diseases with rapid progression and a high mortality rate. Our study aimed to discover the significance of serum sCD25/ferritin ratio as well as cytokines in assisting the diagnosis of LAHS. Methods We retrospectively analyzed the clinical data of 82 patients with LAHS with hemophagocytic lymphohistiocytosis (HLH) as the first manifestation and divided them into B-LAHS group and T/NK-LAHS group according to lymphoma pathological diagnosis for comparison. And patients with LAHS were divided into responding group, non-responding group according to the assessment of efficacy after receiving DEP/L-DEP induction therapy for 2 weeks to compare possible valuable indicators. Results Serum sCD25/ferritin ratio and MCP-1 levels were significantly different between B-LAHS and T/NK-LAHS groups (P = 0.001, P = 0.022). An sCD25/ferritin ratio > 7.8 tended to suggest a diagnosis of B-LAHS (AUC = 0.71, 95% CI: 0.596–0.823), and the sCD25/ferritin ratio had better predictive value when combined with MCP-1 (AUC = 0.81, 95% CI: 0.699–0.922). The sCD25/ferritin ratio was also significantly different between the two groups responding or not responding to induction therapy (P = 0.002), yielding an optimal cutoff value of 11.48. An sCD25/ferritin ratio > 11.48 tended to suggest that the patient’s LAHS was responsive to induction therapy. Conclusion Our study reveals that serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation and may assist in predicting whether the lymphoma is of B-cell or T/NK-cell origin. The sCD25/ferritin ratio can also be used to predict the early response of LAHS after induction therapy.Keywords
Funding Information
- National Natural Science Foundation of China (82170122, 82170122, 82170122, 82170122, 82170122, 82170122, 82170122, 82170122)
- Natural Science Foundation of Beijing Municipality (7181003, 7181003, 7181003, 7181003, 7181003, 7181003, 7181003, 7181003)
This publication has 37 references indexed in Scilit:
- IP-10/CXCL10 and MIG/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndromeAnnals of Hematology, 2013
- Possible prediction of underlying lymphoma by high sIL-2R/ferritin ratio in hemophagocytic syndromeAnnals of Hematology, 2011
- Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathwayBlood, 2010
- Inhibition of Constitutively Activated Nuclear Factor-κB Induces Reactive Oxygen Species- and Iron-Dependent Cell Death in Cutaneous T-Cell LymphomaCancer Research, 2009
- Increased serum monocyte chemoattractant protein‐1, macrophage inflammatory protein‐1β, and interleukin‐8 concentrations in hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2008
- Nationwide Survey of Hemophagocytic Lymphohistiocytosis in JapanInternational Journal of Hematology, 2007
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006
- Effects of nuclear factor‐κB inhibitors and its implication on natural killer T‐cell lymphoma cellsBritish Journal of Haematology, 2005
- Hypercytokinemia in Hemophagocytic SyndromeJournal of Pediatric Hematology/Oncology, 1993
- The Soluble Interleukin-2 Receptor: Biology, Function, and Clinical ApplicationAnnals of Internal Medicine, 1990